Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 6, 2013, Pages 306-315

  Suzuki, Hiromichi ^a   Watanabe, Yusuke ^a   Kumagai, Hiroo ^a   Shuto, Hiroshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

cardiovascular diseases; chronic kidney disease; myopathy; statin

Indexed keywords

CARDIOVASCULAR DISEASES; CHRONIC KIDNEY DISEASE; MYOPATHY; STATIN;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84890507725     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944713513222     Document Type: Article

References (24)

1. Abd T. Jacobson T. (2011) Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10: 373–387.
2. Agarwal R. (2006) Effects of statins on renal function. Am J Cardiol 97: 748–755.
3. Armitage J. (2007) The safety of statins in clinical practice. Lancet 370: 1781–1790.
4. Baigent C. Landray M. Reith C. Emberson J. Wheeler D. Tomson C. et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192.
5. Baumelou A. Bruckert E. Bagnis C. Deray G. (2005) Renal disease in cardiovascular disorders: an underrecognized problem. Am J Nephrol 25: 95–105.
6. Brewer H. Jr (2003) Benefit–risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 92: 23K–29K.
7. Bruckert E. Hayem G. Dejager S. Yau C. Begaud B. (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19: 403–414.
8. Chertow G. Raggi P. McCarthy J. Schulman G. Silberzweig J. Kuhlik A. et al. (2003) The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23: 307–314.
9. Corsini A. Holdaas H. (2005) Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail 27: 259–273.
10. Davidson M. Stein E. Dujovne C. Hunninghake D. Weiss S. Knopp R.H. et al. (1997) The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79: 38–42.
11. Foley R. Parfrey P. Sarnak M. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112–S119.
12. Horio M. Imai E. Yasuda Y. Watanabe T. Matsuo S. (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32–38.
13. Joy T. Hegele R. (2009) Narrative review: statin-related myopathy. Ann Intern Med 150: 858–868.
14. Matsuo S. Imai E. Horio M. Yasuda Y. Tomita K. Nitta K. et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982–992.
15. McKenney J. Davidson M. Jacobson T. Guyton J. (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97: 89C–94C.
16. Mikhailidis D. Lawson R. McCormick A. Sibbring G. Tershakovec A. Davies G.M. et al. (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 27: 1191–1210.
17. Pasternak R. Smith S. Jr Bairey-Merz C. Grundy S. Cleeman J. Lenfant C. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 106: 1024–1028.
18. Sandhu S. Wiebe N. Fried L. Tonelli M. (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17: 2006–2016.
19. Sewright K. Clarkson P. Thompson P. (2007) Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 9: 389–396.
20. Sharma M. Ansari M. Abou-Setta A. Soares-Weiser K. Ooi T. Sears M. et al. (2009) Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 151: 622–630.
21. Silva M. Matthews M. Jarvis C. Nolan N. Belliveau P. Malloy M. et al. (2007) Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29: 253–260.
22. Strippoli G. Navaneethan S. Johnson D. Perkovic V. Pellegrini F. Nicolucci A. et al. (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336: 645–651.
23. Sung J. Nichol M. Venturini F. Bailey K. McCombs J. Cody M. (1998) Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 4: 1421–1430.
24. Upadhyay A. Weiner D. (2012) Lipid-lowering therapy in individuals with CKD: lessons learned from SHARP. Am J Kidney Dis 59: 170–173.